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Abstract
Hepatitis B virus (HBV) produces high quantities of subviral surface antigen particles (HBsAg) which circulate in the blood
outnumbering virions of about 1\10
3–6 times. In individuals coinfected with the defective hepatitis Delta virus (HDV) the
small HDV-RNA-genome and Delta antigen circulate as ribonucleoprotein complexes within HBsAg subviral particles. We
addressed the question whether subviral HBsAg particles may carry in the same way cellular microRNAs (miRNAs) which are
released into the bloodstream within different subcellular forms such as exosomes and microvescicles. Circulating HBsAg
particles were isolated from sera of 11 HBsAg carriers by selective immunoprecipitation with monoclonal anti-HBs-IgG, total
RNA was extracted and human miRNAs were screened by TaqMan real-time quantitative PCR Arrays. Thirty-nine human
miRNAs were found to be significantly associated with the immunoprecipitated HBsAg, as determined by both comparative
DDCT analysis and non-parametric tests (Mann-Whitney, p,0.05) with respect to controls. Moreover immunoprecipitated
HBsAg particles contained Ago2 protein that could be revealed in ELISA only after 0.5% NP40. HBsAg associated miRNAs
were liver-specific (most frequent=miR-27a, miR-30b, miR-122, miR-126 and miR-145) as well as immune regulatory (most
frequent=miR-106b and miR-223). Computationally predicted target genes of HBsAg-associated miRNAs highlighted
molecular pathways dealing with host-pathogen The finding that HBsAg particles carry selective pools of hepatocellular
miRNAs opens new avenues of research to disentangle the complex interactions between host and HBV and provides a non
invasive tool to study the physiopathology of liver epigenetics.
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Introduction
Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus
with complex interactions with the host’s immune system [1–2].
HBV engages the cellular machinery of infected hepatocytes for
the assembly and release of double-shelled 42 nm complete virions
and 20 nm subviral particles [1]. HBV produces extremely high
quantities of hepatitis B surface antigen (HBsAg), the coating
structure of both virions and defective particles which outnumber
virions 10
3–10
6 times [1]. Moreover, in individuals coinfected with
the defective hepatitis delta virus (HDV) the small HDV-RNA
genomes borrow subviral HBsAg particles as outer coats to form
the 36 nm circulating HDV virions [3–4]. Upon replication
mediated by human RNA polymerase II (Pol II) HDV-RNA is
released from hepacytes together with delta antigen (HDAg) as
ribonucleoprotein complex (RNP) within the HBsAg envelope.
The same human Pol II is involved into the synthetic pathway of
microRNAs (miRNAs), a class of important regulatory elements of
cellular epigenetics which are incorporated into specific RNP,
RNA-induced silencing complex (RISC) [5]. MiRNAs have been
increasingly implicated also into intercellular communications, as
they were detected in serum either as free circulating RNA-
induced silencing complexes (RISC) or in association with cell-
derived particulate forms including exosomes and microvescicles
[6–7]. Such a similarity of the RNP-related biological pathways in
both HBV/HDV system and host cells prompted us to investigate
whether HBsAg particles could provide housing to hepatocellular
miRNAs for their release from HBV infected cells and circulation
into the blood. In this study we report the isolation of the
circulating HBsAg fraction from sera of 11 HBV carriers for full
human miRNA profiling by real time quantitative PCR. Specific
repertoires of hepatocellular miRNAs were found to be signifi-
cantly associated with immunoprecipitated HBsAg.
Materials and Methods
Isolation of circulating HBsAg particles
HBsAg particles were immunoprecipitated with anti-HBs-IgG
from 11 sera of HBsAg carriers (phase of HBV infection and
disease was classified as previously reported [8] and 2 HBsAg
negative controls), whose characteristics are described in Table 1.
Sera were pre-cleared by incubation with sepharose-protein G
slurry (GE Healthcare, UK; 120 min at room temperature),
recovered by centrifugation and incubated overnight at 4uC with
preformed sepharose-protein G-IgG complex for either a) HBsAg
immunoprecipitation (where IgG=mouse monoclonal anti-HBs
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Republic  of antibody, Santa-Cruz Biotechnologies, clone 1023), or b) control
immunoprecipitation (where IgG=mouse monoclonal anti-hu-
man c-myc antibody, Invitrogen, clone 9E10.3) (Figure 1). After
centrifugation we obtained leftover sera or flowthroughs and
immunoprecipitated fractions for both HBsAg positive (n=11)
and HBsAg negative (n=2) samples. In parallel, a control
immunoprecipitation was performed on precleared sera of HBsAg
negative controls by incubation with the same mouse anti-HBs-
antibody, providing the corresponding flowthroughs (control anti-
HBs-F, n=2) and immunoprecipitated fractions (control anti-
HBs-IP, n=2). Best immunoprecipitation conditions for the
isolation of circulating HBsAg were obtained by comparing
different antibody-to-resin ratios (from 1 mgt o1 0mg of antibody
every 200 mL of sepharose-protein G slurry) as well as different
starting dilutions of sera (undiluted, 1:10 with PBS pH 7.4, 1:100
with PBS pH 7.4).
An alternative HBsAg immunoprecipitation was performed in
all HBsAg positive sera using Invitrogen Immunoprecipitation Kit-
DynabeadsH Protein G. Briefly the same mouse monoclonal anti-
HBs antibody (10 mg) was crosslinked to 2,8 mm superparamag-
netic beads (50 ml \30 mg/ml) using the cross-linking reagent BS3
(5 mM) and activated beads were used for the HBsAg immuno-
precipitation according to the manufacturer’s specifications.
Ethics Statement
The study was approved by the Ethical Committee of the
University Hospital of Pisa and partecipants gave their written
consent.
Analysis of immunoprecipitated HBsAg by Elisa and
Western blotting
Samples were diluted 1:300 with PBS and tested by commercial
HBsAg ELISA (Bio-Rad). Yields of serum HBsAg depletion were
then calculated as % ratio between OD values of starting sera and
corresponding leftovers. Results were confirmed by quantitative
Architect HBsAg assay (Abbott Laboratories) [8]. For each
immunoprecipitation condition, all samples were analyzed either
individually or pooled together.
Western blotting analysis was performed on all samples or on
pooled samples, in order to evaluate possible serum contaminants
by exosomes. In particular, protein lysates were prepared in 1%
SDS-lysis buffer supplemented with protease inhibitors. Lysates
were mixed with 1 volume of 26SDS sample buffer, denatured,
loaded on 12%SDS-PAGE, and blotted onto nitrocellulose filters
(Millipore, Italy). Filters were hybridized with one of the following
primary antibodies: mouse monoclonal anti-HBs (Santa-Cruz
Biotechnologies, clone 1023), rabbit polyclonal anti-CD63 (Santa-
Cruz Biotechnologies, clone H-193) or rabbit monoclonal (Cell
Signaling, clone C34C6) anti-Ago2. This was followed by
hybridization with secondary anti-mouse or anti-rabbit HRP-
conjugated antibody (GE Healthcare, UK), and detection of
chemiluminescent reaction (ECL plus, Amersham, GE Health-
care, UK).
Serial 1\10 dilutions (in PBS with an without 0.5% NP40
detergent) of the immunoprecipited fractions (IP) from HBsAg
positive and negative sera were tested for Ago2 protein using the
96-well microplates of the HBsAg Elisa Kit (DIA.PRO Diagnostic
Probes Srl. Milan, Italy) coated with monoclonal anti-HBs
antibody.
The assay was carried out according to the protocols of the
manufacturer’s taking care to maintain the same incubation time
for all the samples in testing. IP sample dilutions were incubated
for 120 min at 37uC and after washing additional incubations for
60 min at 37uC were performed respectively for rabbit anti-Ago2
HRP conjugated antibody and rabbit anti-CD63 HRP conjugated
antibody, used as control. After the cromogen\substrate incuba-
tion optical density was measured using a calibrated microplate
reader equipped with a 450 nm filter and a second filter (620–
630 nm) for banking and the S\N 2.1 ratio as positive\negative
cut-off.
Table 1. Demographic and Virologic Characteristics of Individuals and Sera.
Number Age Sex
HBV
Genotype
HBV Infection
Phase
HBsAg
IU/ml
HBV-DNA
IU/ml
ALT
U/l VP SVP SVP/VP
1 32 female D AC2 5459 1.62E+06 288 3.24E+08 4.80E+12 1.48E+04
2 38 male D AC2 12 6.80E+01 32 1.36E+04 1.06E+10 7.76E+05
3 45 male A AC2 4774 2.76E+05 53 5.52E+07 4.20E+12 7.61E+04
4 52 male F AC2 38565 1.50E+03 38 3.00E+05 3.39E+13 1.13E+08
5 49 male CTRL Neg 73
6 55 male CTRL Neg 47
7 40 female D IC 32.17 8.66E+02 10 1.73E+05 2.83E+10 1.63E+05
8 27 male D IC 0.355 5.20E+01 26 1.04E+04 3.12E+08 3.00E+04
9 35 male D AC1 1120 1.09E+03 22 2.17E+05 9.86E+11 4.53E+06
10 47 female D AC1 3955 1.71E+04 42 3.43E+06 3.48E+12 1.02E+06
11 43 female D AC2 26784 ,12 24 2.36E+13
12 51 male D AC2 5394 ,12 28 4.75E+12
13 44 male D AC2 10673 3.37E+04 43 6.74E+06 9.39E+12 1.39E+06
Abbreviations: VP=viral particles, virion; SVP=subviral HBsAg particles; IU=International Units; ng=nanograms; ALT=serum alanine amino trasferase.
Quantitative values for VP and SVP were obtained as previously reported [14–15]: 1 IU of HBsAg corresponds to 1,1E+06 IU HBV DNA and1 ng of HBsAg corresponds to
2,08E+08 SVP or 5,0E+07 VP.
HBV infection and disease phases were characterized as previuosly reported [8]: IC=Inactive HBsAg Carriers with serum HBV-DNA persistently below 2000 IU and
without liver disease; AC1=Active HBsAg Carriers with serum HBV-DNA fluctuating below 20.000 IU with normal liver histology; AC2=Active HBsAg carriers with serum
HBV-DNA fluctuating above 20.000 IU with chronic active hepatitis at histology, patients with chronic hepatitis B (CHB).
doi:10.1371/journal.pone.0031952.t001
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Total RNA was isolated from all samples (whole HBsAg positive
sera, n=11; whole HBsAg negative sera, n=2; HBsAg positive
flowthroughs, n=11; HBsAg negative flowthroughs, n=2; HBsAg
positive IP, n=11;HBsAg negative IP, n=2; control anti-HBs-F,
n2 and control anti-HBs-IP, n=2) by the mirVana miRNA
Isolation kit (Ambion). After treatment with the mirVana miRNA
Isolation kit lysis buffer, samples were added with 3.5 femtomolar
spike-in miRNA (ath-miR-159a Arabidopsis thaliana, Applied Biosys-
tems) before RNA isolation following the manufacturer’s protocol.
The quantity and quality of RNA samples were assessed either by
spectrophotometer at OD260/280 (NanoDrop Technologies Inc.) or
with Quant-iT RiboGreen RNA assay (Invitrogen). Profiling of
miRNAs was carried out using TaqMan-based real time
quantitative PCR (RT-qPCR; all reagents from Applied Biosys-
tems) as previously described [9]. The manufacturer’s Megaplex
protocol with pre-amplification reaction was used; we obtained a
good correlation between CT values with and without the pre-
amplification step and a very good reproducibility (data not
shown). Pre-amplified products of reverse transcription were
finally mounted on 384 microfluidic cards containing the TaqMan
Low Density Arrays (TaqMan Gene Expression assays for 664
human miRNAs accordingly to mirBase v.10.1, also including
duplicate assay for ath-miR-159a) for amplification. RT-qPCR
reactions were run on ABI Prism 7900HT equipped with SDS
software v2.3. Screening of miRNAs in control immunoprecipi-
tates (obtained either with the mouse monoclonal anti-HBs
antibody or mouse monoclonal anti-human c-myc antibody) was
used to determine aspecifically immunoprecipitated serum miR-
NAs for the comparative DDCT analysis of data.
Quantification of miR122 levels was performed in duplicate on
pellets and sera of HBsAg positive and negative subjects by
TaqMan qRT-PCR assay on an Applied BioSystems 7300 HT
thermocycler as previously reported
10 using miR-181a and miR
182c as internal references [10–11]; specific primers were designed
according to the miRBase data base (http://microrna.samger.ac.
uk/). The miRNA levels were calculated according to DCT values
where DCT=mean (Ct of internal reference)2Ct of target
miRNA.
Data analysis, statistics and bioinformatics
Raw CT values were calculated using the SDS software v.2 and
exported as ‘‘Amplification Data’’ text files for each sample.
Exported data were processed with Excel. The global raw CT
values are available in a matrix format as tab delimited text file. As
long as each miRNA in each sample was considered as detected
Figure 1. Isolation of serum HBsAg particles by immunoprecipitation. (a) Defining best immunoprecipitation yields. Upper panel: HBs-ELISA
(BioRad) was used for measuring the depletion of HBsAg from sera under different HBs-immunoprecipitation conditions: antibody-to-resin ratio of
5 mg of antibody every 200 ml of sepharose-protein G slurry was kept since it proved to be the best working condition (not shown), while different
starting dilutions of sera were screened. Depletion was calculated as % ratio of serum HBsAg OD values before and after each HBs-
immunoprecipitation. Error bars indicate SD. C+,C 2: positive and negative controls provided within the kit and used as for manufacturer’s protocol.
Bottom panel: qualitative rendering of HBsAg yields was obtained by Western blot analysis of HBs-immunoprecipitated fractions, followed by
hybridization with mouse monoclonal anti-HBs antibody. (b) The exclusion of concomitant exosomes capture was evidenced by Western blot analysis
of HBs-immunoprecipitated fractions with rabbit anti-CD63 antibody; HEK whole-cell lysate. Panels a-b are descriptive of at least three independent
experiments.
doi:10.1371/journal.pone.0031952.g001
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procedure was performed according to which all values CT$35
were replaced with the chosen threshold of CT=35. Normaliza-
tion was performed against spike-in ath-miR-159a: the mean of ath-
miR-159a amplifications (two for each sample loaded and
amplified on the 384 microfluidic card) was used as the computed
control, and the change in cycling threshold was calculated for
each miRNA (DCT=C T_miRNA2CT_ath).
Both statistical analyses (MeV software version 4.6; unsuper-
vised hierarchical clustering, unsupervised non-parametric Mann-
Withney test, supervised gene distance matrix correlation and data
rendering by single-gradient heatmaps) and the comparative
DDCT calculations were generated from DCT values. In particular,
unsupervised hierarchical clustering either on the whole miRNA
dataset or on significant miRNAs was performed by using the
uncentered Pearson correlation coefficient and complete linkage.
When comparing two groups, a non-parametric Mann-Whitney
test was used to rank differentially expressed miRNAs, as required
by data normality. For all tests, a p,0.05 was considered
significant.
The pools of miRNAs associated with immunoprecipitated
HBsAg were determined by the comparative DDCT method as in
the following algorithm: a) since all control immunoprecipitation
samples clustered together and were clearly separated from the
HBs-IP+ samples (Figure 2, right-most), the whole group of control
immunoprecipitation samples was used as the calibrator subset
(control immunoprecipitates obtained either with the mouse
monoclonal anti-HBs antibody or mouse monoclonal anti-human
c-myc antibody); b) for each miRNA gene, the average normalized
expression value (mean DCT) was calculated across the calibrator
subset (overall n=4); c) the HBsAg positive pellets (n=11) were
considered as target subsets, and DCT values in each sample were
compared to average DCT values of the calibrator subset to
generate DDCT values; d) DDCT values were then used to
calculate the relative quantities (RQ=2
2DDCt) between the
calibrator group and the target subsets. For rendering reasons,
RQ values were rescaled in a logarithmic scale (base 10); e) we
choose a cutoff of 0.5 Log(RQ) corresponding to 3.16 RQ, so that
only RQs above this threshold were taken into account; these
selected RQs were used for studying the distribution of HBsAg-
associated miRNAs among different hepatitis B infection and
disease phases.
When the comparative DDCT analysis was aimed at defining
the circulating HBsAg-miRNA signature, we made further
selection on miRNAs as follows: a) only those miRNAs with
RQs that were successfully selected as described above in at least 2
Figure 2. Differences in Western Blotting and human miRNA analyses between immunoprecipitated HBsAg particles and control
immunoprecipitations. Left-most: Western blotting analysis of protein lysates from HBsAg positive immunoprecipitates (HBs-IP+) and control
HBsAg negative immunoprecipitates (ctrl-IPs) for detection of Ago2 protein. IP+ lanes contain pooled protein lysates from samples # 1–13 and single
lysates from samples # 1 and 9 respectively. Ctrl-IPs lanes contain protein lysates from immunoprecipitates obtained from HBsAg positive sera with
mouse monoclonal anti-human c-myc antibody (unrelated-IP+) and HBsAg negative sera using anti-HBs monoclonal antibody (HBs-IP2). HEK is the
protein lysate from HEK cells used as positive control for Ago2 protein. The figure is representative of 3 independent experiments. Right-most: HCL is
unsupervised hierarchical cluster analysis of detected miRNAs (DCT values) in both HBs-immunoprecipitated fractions from HBsAg positive
immunoprecipitates (HBs-IP+) and control HBsAg negative immunoprecipitates (ctrl-IPs). GDM is supervised gene distance matrix correlating DCt
values of HBs-IP+ vs ctrl-IP samples.
doi:10.1371/journal.pone.0031952.g002
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b) next, average RQs of such selected miRNAs were calculated
across the target HBsAg positive IP samples along with SD and
represented as rescaled logarithmic base 10 plot.
A further refinement of the overall circulating HBsAg-miRNA
signature was made by selecting miRNAs with a non-parametric
Mann-Whitney test (p,0.05) on the average CT values calculated
across the target HBsAg positive IP samples versus the average
DCT values calculated across the calibrator control HBsAg
negative immunoprecipitates.
Targets prediction of HBsAg-associated miRNAs and
functional pathway analysis
Targets prediction was performed for each HBsAg-associated
miRNA of the overall circulating HBsAg-miRNA signature by
TargetScanHuman, release v5.1 (http://www.targetscan.org),
taking into account only conserved target sites. Predicted genes
were then ranked on the basis of a combined parameter
(multiplicative value) obtained by multiplying the TargetScan
total context score by the number of conserved sites. To avoid
exceeding the number of both gene list and predicted pathways,
only targets with multiplicative values #21 were selected and
used as input list for functional pathway exploration by Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems, CA). IPA-
generated top-ranked pathways were determined on the basis of
the incidence of predicted miRNA targets in a list of canonical
pathways provided by the IPA software. Canonical pathways thus
obtained were ranked according to their significance in a Fisher
exact test (p,0.05).
Results
Quantitative purification of HBsAg particles from sera of HBV
carriers was performed by selective immunoprecipitation with
mouse monoclonal anti-HBs antibody to efficiently adjust
experimental conditions and gain the highest reproducible HBsAg
yields. In fact, as long as the isolation of HBsAg fraction from
HBsAg positive samples was aimed at microRNA (miRNA)
profiling studies, high yields were important to meet sensitivity
of real time quantitative PCR (RT-qPCR). To this aim, sepharose-
protein G resin was employed as solid phase for the immunopre-
cipitation reaction because of its high IgG binding capacity, which
allowed for both efficient elimination of IgG contaminants from
sera as well as quantitative depletion of HBsAg from sera. Best
immunoprecipitation conditions were obtained by comparing
different antibody-to-resin ratios (from 1 mgt o1 0mg of antibody
every 200 ml of sepharose-protein G slurry) as well as different
starting dilutions of sera (undiluted, 1:10 with PBS pH 7.4, 1:100
with PBS pH 7.4). In order to evaluate best quantitative yields and
determine reproducibility of HBsAg recovery from sera, we
measured serum HBsAg depletion before and after each
immunoprecipitation by a commercial HBsAg-specific Elisa. For
each immunoprecipitation condition considered, analysis was
taken on both individual and pooled samples. As long as we
found that best working antibody-to-resin ratio was 5 mgo f
antibody every 200 ml of sepharose-protein G slurry (not shown),
we kept this parameter for further fine tuning of the immunopre-
cipitation conditions (Figure 1a, upper panel). In parallel, HBsAg
isolation yields were evaluated by Western blotting of the
immunoprecipitated fractions (HBsAg positive IP samples;
Figure 1a, bottom panel), and compared with HBsAg depletion
yields from sera (Elisa). Elisa and Western blot results unanimously
indicated that in our hands the preparative immunoprecipitation
conditions assuring for optimal balance between highest ratios of
HBsAg depletion from sera (ca 79%) and absolute quantitative
yields of HBsAg into immunoprecipitated fractions were the
following: serum diluted 1:10 with PBS, 5 mg of antibody every
200 ml of sepharose-protein G slurry.
Immunoprecipitation conditions are critical to avoid miRNA
contaminations from other components of sera (principally
exosomes and circulating immunocomplexes which represent
main circulating carriers of human miRNAs in sera), and purity
of HBsAg preparations was as important as quantitative high
yields. Therefore, in setting the HBsAg isolation conditions, a
series of control immunoprecipitations were also undertaken to
assess possible serum contaminants and improve specificity.
Western blotting analysis indicated that HBsAg protein were not
present into the immunoprecipitated fractions of control IPs
(Figure 1a, bottom panel), thus evidencing that both the anti-HBs
antibody used and the selected isolation conditions granted for
specific obtainment of the HBsAg fraction. A consistent evidence
of the lack of exosome contamination was obtained by Western
blotting analysis: nor the enriched HBsAg fractions neither the
control IPs presented any protein signal due to classic exosomal
marker CD63 (Figure 1b).
We looked for the presence of RISC-associated Argonaute2
(Ago2) protein into the immunoprecipitated fractions by Western
blotting, and we found that Ago2 was associated with HBsAg
positive IP (Figure 2, left-most). Using an Elisa with a solid phase
coated with the monoclonal anti-HBs antibody we could reveal the
Ago2 protein with rabbit anti-Ago2 HRP conjugated antibody
only after NP40 treatment (up to 1\1000 dilution in sera 1and 3
which have the highest serum HBsAg levels (Table 1), but not
without NP-40 treatment. Negative results were obtained using
rabbit anti-CD63 HRP conjugated antibody as second antibody.
Based on these overall results, the best HBsAg isolation
condition (serum diluted 1:10 with PBS, 5 mg of antibody every
200 ml of sepharose-protein G slurry) was used throughout the
whole study as it provided highest HBsAg immunoprecipitation
yields, optimal specificity, as well as purity.
To evaluate the presence of human miRNAs within immuno-
precipitated HBsAg fractions, we used RT-qPCR methodology
associated with TaqMan miRNA Arrays which encompass 664
mature miRNAs from the Sanger mirBase v.10.1. The whole
repertoire of human miRNAs was screened in each sample by RT-
qPCR to obtain raw cycle-threshold (CT) expression values. Raw
CT data were then computationally processed as described in
Materials and Methods. For normalization and comparison of
data among individual samples, we used the spike-in ath-miR-159a
as internal standard. The choice was compelled by our
experimental system (virus-related particles), which rendered
impractical the use of established human endogenous/housekeep-
ing genes (e.g., 18S rRNA, GAPDH, ACTB, or small noncoding
miRNAs such as RNU48, RNU44, U6, U18, and U47), as well as
by the fact that to date no established viral miRNA gene from
HBV has been assayed and measured. Moreover, the use of HBV-
DNA amplification by RT-qPCR was considered inefficient
because a) the HBs-immunoprecipitation involved all the reper-
toire of HBsAg-positive circulating particles, namely virions and
defective particles, with great variability of the two fractions from
sample to sample; b) viral load (HBV-DNA serum levels) varies in
relation to HBV infection and disease phase. On the contrary, the
exogenous standard ath-miR-159a assured for technical normal-
ization while being independent of biological variability, and its
use as normalization factor was validated in our hands by
convergent results with the global mean approach (not shown)
which has recently been accepted for miRNA profiling of
biological systems lacking endogenous controls.
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unsupervised hierarchical clustering (HCL, Figure 2, right-most),
all control IP samples clustered together and were clearly
separated from the group of HBsAg positive IP samples. This
fact was well evidenced also by graphical visualization of the whole
DCT dataset as a supervised gene distance correlation matrix
(GDM) built up on the result of the HCL analysis. These
observations indicated the presence of human miRNAs specifically
associated with immunoprecipitated HBsAg particles and prompt-
ed us to characterize miRNA profiling.
In the next step, a comparative DDCT analysis was perfomed to
identify the pools of miRNAs associated with the immunoprecip-
itated HBsAg particles, as described in Materials and Methods.
Since all ctrl-IP samples significantly clustered together (Figure 2,
right-most), the whole group of control IPs was used as the
calibrator subset. On the other hand, the HBsAg positive IP
samples (n=11) were considered as target subsets, and DCT values
in each HBsAg positive IP sample were compared to average DCT
values of the calibrator subset, in order to obtain relative quantity
(RQ) values which describe the ratio of miRNA average
expression levels between each target HBsAg positive IP sample
and the calibrator subset. Only RQs whose value overwhelmed a
fixed threshold of 3.16 (corresponding to a more than three-fold
expression level in each HBsAg positive IP sample with respect to
control IPs) were further selected. As further stringency in the
comparative DDCT analysis, we considered only those miRNAs
with successfully selected RQs in at least 2 of the profiled HBsAg
positive IP samples. Finally, average RQs of thereby selected
miRNAs were calculated across the target HBsAg positive IP
samples along with SD, and represented as rescaled logarithmic
base 10 plot (Figure 3a). Collectively, these HBsAg-associated
miRNAs were used throughout the study as the circulating
HBsAg-miRNA signature.
In order to verify the pool of HBsAg-associated human miRNAs
identified by the comparative DDCT analysis described so far, a
different approach was used in which the individual DCT values of
each HBsAg positive IP sample were directly compared to
individual DCT values of each control IP sample within a two
experimental groups, non-parametric Mann-Whitney test followed
by hierarchical clustering on significant genes. The analysis was
aimed at determining those miRNAs with significant differentiated
detection levels between the two groups, and it was first performed
by engaging all of the HBsAg positive IP samples. As shown in
Figure 3b (left panel) the Mann-Whitney test led to a pool of 11
miRNAs that were significantly associated to the immunoprecip-
itated HBsAg particles and were all contained within the group of
HBsAg-associated human miRNAs identified by the comparative
DDCT analysis (Figure 3a) with the exception of miR-513-3p and
miR-378 (Venn diagram in the Figure 3b, left panel). In fact these
2 miRNAs presented a great SD because of the strongly
heterogeneous level distribution among samples, leading to their
exclusion from the comparative DDCT analysis of Figure 3a.
Given the heterogeneity of the examined samples belonging to
different HBV infection and disease phases, the two experimental
groups, non-parametric Mann-Whitney test was then repeated on
a smaller group of HBsAg positive IP samples, belonging to the
AC2 phase of HBV infection (Table 1), namely patients with
chronic hepatitis B (CHB) (Figure 3b, right panel). As expected,
the reduction of the heterogeneity of samples produced a larger
number of miRNAs significantly associated with immunoprecip-
itated HBsAg. All of the identified miRNAs belonged to the
circulating HBsAg-miRNA signature defined in the comparative
DDCT analysis of Figure 3a, with the exception of a few HBsAg-
associated miRNAs which were negatively selected by the DDCT
analysis because of high SD values (Venn diagram in the Figure 3b,
left panel). In this second Mann-Whitney analysis, the differenti-
ated repertoires of human miRNAs that significantly associated
with the immunoprecipitated HBsAg particles were organized into
clusters 1–4. Aspecifically immunoprecipitated miRNAs were
grouped in cluster 5. In particular, HBsAg-associated miRNAs in
clusters 2–4 were characterized by a significant decrease of their
serum levels upon the HBs-immunoprecipitation. Following this
latter observation, a Mann-Whitney test was also performed on
normalized DCT values of whole HBsAg positive sera and HBsAg
positive flowthroughs from the examined samples # 1–4 of the
AC2 phase of HBV infection, CHB (Table 1). The heatmap of
differentially detected miRNAs (Figure 4) clearly shows that a
number of serum miRNAs (including the identified HBsAg-
associated miRNAs of Figure 3) underwent a significant change-
fold of detected levels upon the HBs-immunoprecipitation. In
particular, when comparing by Venn analysis the 157 differentially
abundant serum miRNAs between whole HBsAg positive sera and
HBsAg positive flowthroughs to the miRNAs obtained by the
Mann-Whitney test of Figure 2s (right panel, clusters 1-to-5), it was
observed that miRNAs from clusters 2–4 fall in the set of the 37
common miRNAs (Venn diagram of Figure 3b), thus contributing
to the observed serum differences upon HBs-immunoprecipitation,
the rest being represented by aspecifically immunoprecipitated
miRNAs of cluster 5. To analyse the quantitative relations
between hepatocellular miRNA and HBsAg we measured the
levels of the most frequent and more abundant liver specific
miRNA, miR-122 by qRT-PCR and found that median miR122
levels were significantly (p,0.001) higher in pellets (42.1 in HBsAg
positive and 0.19 in HBsAg negative samples) vs whole HBsAg
positive and negative sera respectively (0.41 and 0.05) showing a
significant enrichment (.100 fold) of miR-122 in HBsAg positive
pellets vs whole sera and about 20 fold increase in HBsAg positive
vs HBsAg negative pellets.
We assessed the putative target genes of these miRNAs by a
well-established miRNA-target prediction software, TargetScan.
The algorithm was used with default parameters, but in order to
increase the stringency we selected miRNA-targets within a given
threshold (Materials and Methods). Top-scoring miRNA-targets
were then used as input list for a functional pathway analysis by
Ingenuity Pathway Analysis software, a well-established tool for in
silico evaluation of pathways involving candidate target genes.
HBsAg-associated miRNAs and their putative targets were
significantly linked to 3 canonical pathways dealing with
clathrin-mediated endocytosis, virus entry via endocytosys and
dendritic cell maturation (Figure 5).
Discussion
In the present study we show for the first time that HBsAg
particles circulating in HBV carriers carry hepatocellular miRNAs
and the Ago2 associated protein. The immunoprecipitation of
HBsAg from whole serum leads to significant quantitative changes
between miRNA levels before and after HBsAg particle depletion
whereas this does not occur after control immunoprecipitations.
One hundred and fifty seven miRNA decreased significantly
after HBsAg immunoprecipitation (Mann-Whitney test p,0.05,
Figure 4); 39 of them were HBsAg associated according to them
DDCt comparative analysis (Figure 3a), 31 (Mann-Whitney test
p,0.05) if considering only patients with chronic hepatitis B.
Using for HBsAg immunoprecipitation the same mouse mono-
clonal anti-HBs antibody crosslinked to 2,8 mm superparamag-
netic beads we obtained a good correspondence in the output of
HBsAg associated miRNAs (32\39, 82.05%). These results
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overall serum miRNA profile.
The great majority of the hepatocytes of HBV carriers are
infected and produce subviral HBsAg particles as well as complete
virions, but subviral particles outnumber virions (between 10.000–
1.000.000 times in our cases, see Table 1). Accordingly, we found
that most of HBsAg-associated miRNAs (namely, miR-122, miR-
27a, miR-29a, miR-30a, miR-30b, miR-126, miR-145, miR-223)
belong to the previously described repertoires of miRNAs
differentially expressed in liver development, disease, fibrosis
and/or regeneration [16–22].
Capturing the circulating HBsAg particles with a solid phase
coated with the same monoclonal anti-HBs antibody used for the
immunoprecipitation we could demonstrate that Ago2 protein can
Figure 3. Identification of human miRNAs associated with serum HBsAg. (a) The circulating HBsAg-miRNA signature: average RQs were
obtained from the comparative DDCT analysis. Values are reported in a bar plot as a logarithmic scale base 10 along with SD. (b) Differentially
detected miRNAs between HBsAg positive immunoprecipitates (HBs-IP+) samples (left-most, n=11; right-most, n=4) and the group of control HBsAg
negative immunoprecipiates (ctrl-IPs) (n=4) were selected by Mann-Whitney test on –DCt values (left-most, p,0.1; right-most, p,0.05), and an
unsupervised hierarchical cluster analysis was finally performed. Venn diagrams indicate the comparison among the pool of HBsAg-associated
miRNAs obtained from the comparative DDCT analysis of panel a (blu circle) and the HBsAg-associated miRNAs obtained from the Mann-Whitney
tests (red circle).
doi:10.1371/journal.pone.0031952.g003
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NP40 treatment, but not without the disruption of the lipoprotein
envelope by detergent treatment. In addition negative results were
obtained using the control anti-CD63 HRP labeled polyclonal
antibody as second antibody. These results provide consistent
evidence that subviral HBsAg particles can carry inside miRNA
and associated Ago2 protein in the same way as it was previously
shown for HDV-RNA and HDAg complexes [3–4].
By measuring the most frequent and abundant mi-122 by qRT-
PCR we attempted to normalize the amount of miR-122 to the
respective HBsAg levels and with the limitation of the simplified
simulation we found that there is a direct relation between the
overall amount of HBsAg and miRNA in the testing material.
However, this issue will be more properly addressed only by
studying the 3D ultrastructure of HBsAg subviral particles in the
electron microscope. As far as the possible functional activity of
HBsAg associated miRNA we may only speculate that their
amount appear significantly higher than in the exosomal and
microvescicular compartments of the same sera. Recently is has
been shown that miRNA carried by exosomes are biologically
active once exosomes are internalized within cells [23]. However,
we believe that the most relevant finding of our work is the
identification of a new tool for non invasive liver specific miRNAs
profiling that allows to study in simple serum specimens the
dynamic changes of hepatocellular miRNA expression profiles in
both physiologic and pathologic conditions. Interestingly we found
a 30% correspondence between our results and those of Ji F et al.
[10] who studied the overall serum miRNA profile of HBV
infected patients. Interestingly we detected 5 of 9 miRNA, more
frequently circulating in their HBsAg carriers: miR-19b, miR-122
and miR-223 were associated with HBsAg positive immunopre-
cipitates whereas miR-16 and miR-20a were detected in control
immunoprecipitates.
Different studies highlight the emerging role of miRNAs in host-
pathogen interactions not only in plants and invertebrates, where
miRNA-mediated RNA interference represents an innate antiviral
immune response, but also in mammals [24]. Accordingly, liver-
specific miR-122 was previously shown to be essential for hepatitis
C virus replication [16,25] and upregulated in HBV infected
patients [26]. Some of HBsAg-associated miRNAs were reported
to play a role in human carcinogenesis. Down-regulation of miR-
122 and miR-223 was hyptohesized to be relevant for hepatocel-
lular carcinoma development [18,19,27]. Recently Gao et al. [26]
proposed miR-145 as a candidate tumor suppressive miRNA in
the early steps of HBV related hepatocarcinogenesis.
In addition some of the HBsAg-associated miRNAs identified in
the present study are directly involved in development/function of
the myeloid lineage, as well as in the regulation of innate immunity
(miR-223) and lymphocytes (miR-106b and miR-19b of the two
mammalian paralog clusters miR-17,92 and miR-106b,25)
[24].
On the basis of these considerations, the analysis of target genes
of HBsAg-associated miRNAs and the related functional pathway
analysis provided results which are strongly compatible with the
biological activity of the identified miRNAs. In fact, computa-
tionally predicted target genes of HBsAg-associated miRNAs
appeared significantly involved into molecular mechanisms
canonically dealing with host-virus interaction, such as clathrin-
mediated endocytosis, virus entry, and dendritic cell maturation.
Interestingly, the finding that host-virus interaction pathways are
over-represented among predicted targets of HBsAg associated-
miRNAs suggests the intriguing hypothesis that circulating HBsAg
particles carrying host cellular miRNAs might have an important
role in the complex mechanisms of viral spreading, persistence and
pathogenesis. This hypothesis is consistent with the evidence that
HBsAg serum levels, resulting from the equilibrium between virus
Figure 4. HBs-immunoprecipitation led to a significant change of detection of some human miRNAs in examined sera. Heatmap of
differentially detected miRNAs in whole HBsAg sera (S+) and HBsAg positive flowthroughs after immunoprecipitation (HBs-F+) was obtained by
Mann-Whitney test (p,0.05) followed by hierarchical clustering (-DCT are represented). Venn diagram: the 157 differentially abundant serum miRNAs
between whole HBsAg positive sera (S+) and HBsAg positive flowthroughs (HBs-F+) were compared to miRNAs of clusters 1-to-5 in Figure 3b (right
panel).
doi:10.1371/journal.pone.0031952.g004
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infection and reach the lowest values in the inactive HBsAg
carriers [8,28].The small number of cases of the present study does
not allow any speculation on the role of different miRNAs,
selectively associated with circulating HBsAg in the different
phases of HBV infection and disease.
In conclusion, the finding that HBsAg particles carry hepato-
cellular miRNAs opens new avenues of research to disentangle the
complex interaction between host and HBV. HBsAg associated-
miRNAs might play a pivotal role in viral persistence and help to
explain the clinical evidence that the most efficient immune
control of HBV infection associates with the loss of serum HBsAg.
Profiling the in vivo HBsAg-associated miRNAs dynamics in
different cohorts of HBsAg carriers provides a unique model for
studing the epigenetics of liver physiopathology in viral and non
viral diseases.
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